Persistent immune abnormalities discriminate post-COVID syndrome from convalescence.

COVID-19 Immune activation Innate lymphoid cells Post-COVID-19-syndrome Tissue immunology

Journal

Infection
ISSN: 1439-0973
Titre abrégé: Infection
Pays: Germany
ID NLM: 0365307

Informations de publication

Date de publication:
07 Feb 2024
Historique:
received: 13 11 2023
accepted: 19 12 2023
medline: 8 2 2024
pubmed: 8 2 2024
entrez: 7 2 2024
Statut: aheadofprint

Résumé

Innate lymphoid cells (ILCs) are key organizers of tissue immune responses and regulate tissue development, repair, and pathology. Persistent clinical sequelae beyond 12 weeks following acute COVID-19 disease, named post-COVID syndrome (PCS), are increasingly recognized in convalescent individuals. ILCs have been associated with the severity of COVID-19 symptoms but their role in the development of PCS remains poorly defined. Here, we used multiparametric immune phenotyping, finding expanded circulating ILC precursors (ILCPs) and concurrent decreased group 2 innate lymphoid cells (ILC2s) in PCS patients compared to well-matched convalescent control groups at > 3 months after infection or healthy controls. Patients with PCS showed elevated expression of chemokines and cytokines associated with trafficking of immune cells (CCL19/MIP-3b, FLT3-ligand), endothelial inflammation and repair (CXCL1, EGF, RANTES, IL-1RA, PDGF-AA). These results define immunological parameters associated with PCS and might help find biomarkers and disease-relevant therapeutic strategies.

Sections du résumé

BACKGROUND BACKGROUND
Innate lymphoid cells (ILCs) are key organizers of tissue immune responses and regulate tissue development, repair, and pathology. Persistent clinical sequelae beyond 12 weeks following acute COVID-19 disease, named post-COVID syndrome (PCS), are increasingly recognized in convalescent individuals. ILCs have been associated with the severity of COVID-19 symptoms but their role in the development of PCS remains poorly defined.
METHODS AND RESULTS RESULTS
Here, we used multiparametric immune phenotyping, finding expanded circulating ILC precursors (ILCPs) and concurrent decreased group 2 innate lymphoid cells (ILC2s) in PCS patients compared to well-matched convalescent control groups at > 3 months after infection or healthy controls. Patients with PCS showed elevated expression of chemokines and cytokines associated with trafficking of immune cells (CCL19/MIP-3b, FLT3-ligand), endothelial inflammation and repair (CXCL1, EGF, RANTES, IL-1RA, PDGF-AA).
CONCLUSION CONCLUSIONS
These results define immunological parameters associated with PCS and might help find biomarkers and disease-relevant therapeutic strategies.

Identifiants

DOI: 10.1007/s15010-023-02164-y PMID: 38326527
pubmed: 38326527
doi: 10.1007/s15010-023-02164-y
pii: 10.1007/s15010-023-02164-y
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. The Author(s).

Références

Clark DV, Kibuuka H, Millard M, Wakabi S, Lukwago L, Taylor A, et al. Long-term sequelae after Ebola virus disease in Bundibugyo, Uganda: a retrospective cohort study. Lancet Infect Dis. 2015;15:905–12. https://doi.org/10.1016/S1473-3099(15)70152-0 .
doi: 10.1016/S1473-3099(15)70152-0 pubmed: 25910637
A Post-Graduate Lecture ON THE NERVOUS SEQUELÆ OF INFLUENZA. Lancet 1893;142:73–6. https://doi.org/10.1016/S0140-6736(00)65088-2 .
Fluge Ø, Tronstad KJ, Mella O. Pathomechanisms and possible interventions in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). J Clin Invest 2021. https://doi.org/10.1172/JCI150377 .
Newton DJ, Kennedy G, Chan KKF, Lang CC, Belch JJF, Khan F. Large and small artery endothelial dysfunction in chronic fatigue syndrome. Int J Cardiol. 2012;154:335–6. https://doi.org/10.1016/j.ijcard.2011.10.030 .
doi: 10.1016/j.ijcard.2011.10.030 pubmed: 22078396
Datta SD, Talwar A, Lee JT. A proposed framework and timeline of the spectrum of disease due to SARS-CoV-2 infection: illness beyond acute infection and public health implications. JAMA. 2020;324:2251–2. https://doi.org/10.1001/jama.2020.22717 .
doi: 10.1001/jama.2020.22717 pubmed: 33206133
Sivan M, Taylor S. NICE guideline on long covid. BMJ. 2020;371:m4938. https://doi.org/10.1136/bmj.m4938 .
doi: 10.1136/bmj.m4938 pubmed: 33361141
Crook H, Raza S, Nowell J, Young M, Edison P. Long covid—mechanisms, risk factors, and management. BMJ. 2021;374:n1648. https://doi.org/10.1136/bmj.n1648 .
doi: 10.1136/bmj.n1648 pubmed: 34312178
Margalit I, Yelin D, Sagi M, Rahat MM, Sheena L, Mizrahi N, et al. Risk factors and multidimensional assessment of long coronavirus disease fatigue: a nested case-control study. Clin Infect Dis. 2022;75:1688–97. https://doi.org/10.1093/cid/ciac283 .
doi: 10.1093/cid/ciac283 pubmed: 35403679
Choutka J, Jansari V, Hornig M, Iwasaki A. Unexplained post-acute infection syndromes. Nat Med. 2022;28:911–23. https://doi.org/10.1038/s41591-022-01810-6 .
doi: 10.1038/s41591-022-01810-6 pubmed: 35585196
Kreutmair S, Unger S, Núñez NG, Ingelfinger F, Alberti C, De Feo D, et al. Distinct immunological signatures discriminate severe COVID-19 from non-SARS-CoV-2-driven critical pneumonia. Immunity. 2021;54:1578-1593.e5. https://doi.org/10.1016/j.immuni.2021.05.002 .
doi: 10.1016/j.immuni.2021.05.002 pubmed: 34051147 pmcid: 8106882
Bergamaschi L, Mescia F, Turner L, Hanson AL, Kotagiri P, Dunmore BJ, et al. Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease. Immunity. 2021;54:1257-1275.e8. https://doi.org/10.1016/j.immuni.2021.05.010 .
doi: 10.1016/j.immuni.2021.05.010 pubmed: 34051148 pmcid: 8125900
Blot M, Bour J-B, Quenot JP, Bourredjem A, Nguyen M, Guy J, et al. The dysregulated innate immune response in severe COVID-19 pneumonia that could drive poorer outcome. J Transl Med. 2020;18:457. https://doi.org/10.1186/s12967-020-02646-9 .
doi: 10.1186/s12967-020-02646-9 pubmed: 33272291 pmcid: 7711269
Lim J, Puan KJ, Wang LW, Teng KWW, Loh CY, Tan KP, et al. Data-driven analysis of COVID-19 reveals persistent immune abnormalities in convalescent severe individuals. Front Immunol 2021;12.
Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. The Lancet. 2020;395:1417–8. https://doi.org/10.1016/S0140-6736(20)30937-5 .
doi: 10.1016/S0140-6736(20)30937-5
Cheon IS, Li C, Son YM, Goplen NP, Wu Y, Cassmann T, et al. Immune signatures underlying post-acute COVID-19 lung sequelae. Sci Immunol. 2022;6:1741. https://doi.org/10.1126/sciimmunol.abk1741 .
doi: 10.1126/sciimmunol.abk1741
Klein J, Wood J, Jaycox J, Lu P, Dhodapkar RM, Gehlhausen JR, et al. Distinguishing features of Long COVID identified through immune profiling. MedRxiv. 2022. https://doi.org/10.1101/2022.08.09.22278592 .
doi: 10.1101/2022.08.09.22278592 pubmed: 36597525 pmcid: 9810233
Phetsouphanh C, Darley DR, Wilson DB, Howe A, Munier CML, Patel SK, et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol. 2022;23:210–6. https://doi.org/10.1038/s41590-021-01113-x .
doi: 10.1038/s41590-021-01113-x pubmed: 35027728
Moro K, Yamada T, Tanabe M, Takeuchi T, Ikawa T, Kawamoto H, et al. Innate production of TH2 cytokines by adipose tissue-associated c-Kit+Sca-1+ lymphoid cells. Nature. 2010;463:540–4. https://doi.org/10.1038/nature08636 .
doi: 10.1038/nature08636 pubmed: 20023630
Vivier E, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G, et al. Innate lymphoid cells: 10 years on. Cell. 2018;174:1054–66. https://doi.org/10.1016/j.cell.2018.07.017 .
doi: 10.1016/j.cell.2018.07.017 pubmed: 30142344
Annunziato F, Romagnani C, Romagnani S. The 3 major types of innate and adaptive cell-mediated effector immunity. J Allergy Clin Immunol. 2015;135:626–35. https://doi.org/10.1016/j.jaci.2014.11.001 .
doi: 10.1016/j.jaci.2014.11.001 pubmed: 25528359
Cautivo KM, Matatia PR, Lizama CO, Mroz NM, Dahlgren MW, Yu X, et al. Interferon gamma constrains type 2 lymphocyte niche boundaries during mixed inflammation. Immunity. 2022;55:254-271.e7. https://doi.org/10.1016/j.immuni.2021.12.014 .
doi: 10.1016/j.immuni.2021.12.014 pubmed: 35139352 pmcid: 8852844
Dahlgren MW, Molofsky AB. All along the watchtower: group 2 innate lymphoid cells in allergic responses. Curr Opin Immunol. 2018;54:13–9.
doi: 10.1016/j.coi.2018.05.008 pubmed: 29860003 pmcid: 6460905
Gomez-Cadena A, Spehner L, Kroemer M, Khelil MB, Bouiller K, Verdeil G, et al. Severe COVID-19 patients exhibit an ILC2 NKG2D+ population in their impaired ILC compartment. Cell Mol Immunol. 2021;18:484–6. https://doi.org/10.1038/s41423-020-00596-2 .
doi: 10.1038/s41423-020-00596-2 pubmed: 33318627
Silverstein NJ, Wang Y, Manickas-Hill Z, Carbone C, Dauphin A, Boribong BP, et al. Innate lymphoid cells and COVID-19 severity in SARS-CoV-2 infection. Elife. 2022;11:e74681. https://doi.org/10.7554/eLife.74681 .
doi: 10.7554/eLife.74681 pubmed: 35275061 pmcid: 9038195
Pritsch M, Radon K, Bakuli A, Le Gleut R, Olbrich L, Guggenbüehl Noller JM, et al. Prevalence and risk factors of infection in the representative COVID-19 cohort Munich. Int J Environ Res Public Health. 2021. https://doi.org/10.3390/ijerph18073572 .
doi: 10.3390/ijerph18073572 pubmed: 33808249 pmcid: 8038115
Radon K, Saathoff E, Pritsch M, Guggenbühl Noller JM, Kroidl I, Olbrich L, et al. Protocol of a population-based prospective COVID-19 cohort study Munich, Germany (KoCo19). BMC Public Health. 2020;20:1036. https://doi.org/10.1186/s12889-020-09164-9 .
doi: 10.1186/s12889-020-09164-9 pubmed: 32605549 pmcid: 7324773
Brand I, Gilberg L, Bruger J, Garí M, Wieser A, Eser TM, et al. Broad T cell targeting of structural proteins after SARS-CoV-2 infection: high throughput assessment of T cell reactivity using an automated interferon gamma release assay. Front Immunol 2021;12.
Mazzurana L, Bonfiglio F, Forkel M, D’Amato M, Halfvarson J, Mjösberg J. Crohn’s disease is associated with activation of circulating innate lymphoid cells. Inflamm Bowel Dis. 2021;27:1128–38. https://doi.org/10.1093/ibd/izaa316 .
doi: 10.1093/ibd/izaa316 pubmed: 33295628
Kotecha N, Krutzik PO, Irish JM. Web-based analysis and publication of flow cytometry experiments. Curr Protoc Cytom 2010;Chapter 10:Unit10.17-Unit10.17. https://doi.org/10.1002/0471142956.cy1017s53 .
Rogers WT, Holyst HA. FlowFP: a bioconductor package for fingerprinting flow cytometric data. Adv Bioinform. 2009;2009:193947. https://doi.org/10.1155/2009/193947 .
doi: 10.1155/2009/193947
Lim AI, Li Y, Lopez-Lastra S, Stadhouders R, Paul F, Casrouge A, et al. Systemic human ILC precursors provide a substrate for tissue ILC differentiation. Cell. 2017;168:1086-1100.e10. https://doi.org/10.1016/j.cell.2017.02.021 .
doi: 10.1016/j.cell.2017.02.021 pubmed: 28283063
Kokkinou E, Pandey RV, Mazzurana L, Gutierrez-Perez I, Tibbitt CA, Weigel W, et al. CD45RA+CD62L− ILCs in human tissues represent a quiescent local reservoir for the generation of differentiated ILCs. Sci Immunol. 2023;7:eabj8301. https://doi.org/10.1126/sciimmunol.abj8301 .
doi: 10.1126/sciimmunol.abj8301
Fonseca W, Lukacs NW, Elesela S, Malinczak C-A. Role of ILC2 in Viral-Induced Lung Pathogenesis. Front Immunol 2021;12.
Vanoni G, Ercolano G, Candiani S, Rutigliani M, Lanata M, Derré L, et al. Human primed ILCPs support endothelial activation through NF-κB signaling. Elife. 2021;10:e58838. https://doi.org/10.7554/eLife.58838 .
doi: 10.7554/eLife.58838 pubmed: 33554861 pmcid: 7891932
Kaiser R, Leunig A, Pekayvaz K, Popp O, Joppich M, Polewka V, et al. Self-sustaining IL-8 loops drive a prothrombotic neutrophil phenotype in severe COVID-19. JCI Insight. 2021. https://doi.org/10.1172/jci.insight.150862 .
doi: 10.1172/jci.insight.150862 pubmed: 34403366 pmcid: 8492337
Sabbatino F, Conti V, Franci G, Sellitto C, Manzo V, Pagliano P, et al. PD-L1 dysregulation in COVID-19 patients. Front Immunol 2021;12.
Zhang Z, Ai G, Chen L, Liu S, Gong C, Zhu X, et al. Associations of immunological features with COVID-19 severity: a systematic review and meta-analysis. BMC Infect Dis. 2021;21:738. https://doi.org/10.1186/s12879-021-06457-1 .
doi: 10.1186/s12879-021-06457-1 pubmed: 34344353 pmcid: 8329624
Antonelli M, Penfold RS, Merino J, Sudre CH, Molteni E, Berry S, et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis. 2022;22:43–55. https://doi.org/10.1016/S1473-3099(21)00460-6 .
doi: 10.1016/S1473-3099(21)00460-6 pubmed: 34480857 pmcid: 8409907
Magnusson K, Kristoffersen DT, Dell’Isola A, Kiadaliri A, Turkiewicz A, Runhaar J, et al. Post-covid medical complaints following infection with SARS-CoV-2 Omicron vs Delta variants. Nat Commun. 2022;13:7363. https://doi.org/10.1038/s41467-022-35240-2 .
doi: 10.1038/s41467-022-35240-2 pubmed: 36450749 pmcid: 9709355

Auteurs

Julia Sbierski-Kind (J)

Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
Department of Internal Medicine IV, Division of Diabetology, Endocrinology and Nephrology, University Hospital, Eberhard-Karls-Universität Tübingen, Tübingen, Germany.
The M3 Research Center, University Clinic Tübingen (UKT), Medical Faculty, Otfried-Müllerstr. 37, Tübingen, Germany.

Stephan Schlickeiser (S)

Charité, Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt- Universität Zu Berlin, Institute of Medical Immunology, Augustenburger Platz 1, 13353, Berlin, Germany.
Berlin Institute of Health (BIH) at Charité, Universitätsmedizin Berlin, BIH Center for Regenerative Therapies (BCRT), Charitéplatz 1, 10117, Berlin, Germany.

Svenja Feldmann (S)

Department of Infectious Diseases, Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.

Veronica Ober (V)

Department of Infectious Diseases, Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.

Eva Grüner (E)

Department of Infectious Diseases, Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.

Claire Pleimelding (C)

Department of Infectious Diseases, Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.

Leonard Gilberg (L)

Department of Infectious Diseases, Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.

Isabel Brand (I)

German Center for Infection Research (DZIF), Partner Site Munich, Munich, Germany.

Nikolas Weigl (N)

Department of Medicine IV, Division of Clinical Pharmacology, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.

Mohamed I M Ahmed (MIM)

German Center for Infection Research (DZIF), Partner Site Munich, Munich, Germany.
Division of Infectious Diseases and Tropical Medicine, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.

Gerardo Ibarra (G)

The M3 Research Center, University Clinic Tübingen (UKT), Medical Faculty, Otfried-Müllerstr. 37, Tübingen, Germany.
COVID-19 Registry of the LMU Munich (CORKUM), University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.

Michael Ruzicka (M)

COVID-19 Registry of the LMU Munich (CORKUM), University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany.

Christopher Benesch (C)

COVID-19 Registry of the LMU Munich (CORKUM), University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
Department of Medicine II, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.

Anna Pernpruner (A)

COVID-19 Registry of the LMU Munich (CORKUM), University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
Department of Medicine II, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.

Elisabeth Valdinoci (E)

COVID-19 Registry of the LMU Munich (CORKUM), University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
Department of Medicine II, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.

Michael Hoelscher (M)

German Center for Infection Research (DZIF), Partner Site Munich, Munich, Germany.
Division of Infectious Diseases and Tropical Medicine, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.

Kristina Adorjan (K)

COVID-19 Registry of the LMU Munich (CORKUM), University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
Department of Psychiatry and Psychotherapy, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.

Hans Christian Stubbe (HC)

German Center for Infection Research (DZIF), Partner Site Munich, Munich, Germany.
COVID-19 Registry of the LMU Munich (CORKUM), University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
Department of Medicine II, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.

Michael Pritsch (M)

German Center for Infection Research (DZIF), Partner Site Munich, Munich, Germany.
Division of Infectious Diseases and Tropical Medicine, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.

Ulrich Seybold (U)

Department of Infectious Diseases, Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.

Julia Roider (J)

Department of Infectious Diseases, Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany. Julia.Roider@med.uni-muenchen.de.
German Center for Infection Research (DZIF), Partner Site Munich, Munich, Germany. Julia.Roider@med.uni-muenchen.de.

Classifications MeSH